{"id":"W4400914165","doi":"10.1016/j.jaad.2024.06.097","title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; University of Calgary; Lynde Centre for Dermatology; Université de Montréal; Heritage Medical Research Clinic; Probity Medical Research; Institute of Cosmetic and Laser Surgery; University of Toronto","funders":"LEO Pharma; Bausch Health; Coherus Biosciences; Glenmark Pharmaceuticals; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Sanofi; Amgen; Concert Pharmaceuticals; Pfizer; Celgene; Galderma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Alopecia areata; Medicine; Janus kinase; Janus kinase inhibitor; Hair loss; Dermatology; Randomized controlled trial; Hair growth; Safety profile; Janus; Pharmacology; Adverse effect; Internal medicine; Physiology; Nanotechnology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002579246,0.0008289827,0.00180176,0.0002645547,0.0003819974,0.0009407059,0.0004522717,0.001559319,0.003406737],"category_scores_gemma":[0.002308045,0.0003199736,0.00248118,0.0003042406,0.0005743513,0.0006688767,0.0002293739,0.002307367,0.0004817675],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005680443,"about_ca_system_score_gemma":0.0008314018,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006318525,"about_ca_topic_score_gemma":0.001560449,"domain_scores_codex":[0.9991003,0.0004676741,0.00009894908,0.0001298913,0.0001034848,0.00009963474],"domain_scores_gemma":[0.9984079,0.0004350531,0.0005849334,0.00007532984,0.0001437411,0.0003529392],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.915692,0.00764368,0.004753572,0.001924787,0.003265779,0.0001265265,0.0001326082,0.000400758,0.007921115,0.0001289833,0.002647582,0.05536262],"study_design_scores_gemma":[0.8663166,0.1084723,0.0197415,0.0001518346,0.002015977,0.0002210909,0.00004663044,0.000383142,0.0008621793,0.0001313741,0.001634427,0.00002291027],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9636998,0.02671766,0.0005125441,0.00139096,0.0004206081,0.002068,0.002205895,0.0001091371,0.002875324],"genre_scores_gemma":[0.9854475,0.006832686,0.000918965,0.001756188,0.0005233075,0.00158948,0.001799061,0.00001828413,0.001114459],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003406737,"threshold_uncertainty_score":0.01364052,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01082880236941663,"score_gpt":0.3073237314717573,"score_spread":0.2964949291023407,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}